Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-08-09
2005-08-09
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S560000, C514S562000, C514S563000, C560S150000, C560S153000, C562S557000
Reexamination Certificate
active
06927236
ABSTRACT:
The present invention relates to compounds of the formulawhich are formed during fermentation by the microorganismConiochaeta ellipsoideaUdagawa, DSM 13856, or by one of its mutations and/or variants, and chemically derivatized if appropriate. The invention furthermore relates to a process for preparing compounds of the formula (I), and to their use as pharmaceuticals. In addition, the invention relates to the use of a compound of the formula (VI)for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.
REFERENCES:
patent: WO 98/21327 (1998-05-01), None
Lue et al, “Soluble Amyloid beta Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease” American Journal of Pathology, vol. 155(3), pp. 853-862 (1999).
Mclean et al, “Soluble Pool of A-beta Amyloid as a Determinant of Severity of Neurodegeneration in Alzheimer's Disease” Annals of Neurology, vol. 46(6), pp. 860-866 (Dec. 1999).
Reichman, W.E., “Alzheimer's Disease: Clinical Treatment Options” vol. 6(22) Sup., pp. S1125-S1138 (Dec. 2000).
Sabo et al, “The Alzheimer Amyloid Precursor Protein (APP) and FE65, an APP-binding Protein, Regulate Cell Movement” The Journal of Cell Biology, vol. 153, pp. 1403-1414 (2001).
Klein, W., “A.beta. toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets” Neurochemist International, vol. 41, pp. 345-352 (2002).
Bryant A. Gilbert et al., Structure- Activity Studies on the Retinal Rod Outer Segment Isoprenylated Protein Methytransferase, J. Am. Chem. Soc. (1992, pp. 3966-3973, vol. 114).
Dennis Selkoe, The Cell Biology of b-amyloid precursor protein and presenilin in Alzheimer's Disease, Trends in Cell Biology (1998, pp. 447-453, vol. 8).
Eng Wui Tan et al., Heteroatom Requirements for Substrate Recognition by GTP-Binding Protein Methyltransferase, J. Am. Chem. Soc. (1991, pp. 6299-6300, vol. 113).
Glomset, J.A., Prenyl proteins in eukaryotic cells: a new type of membrance anchor, Trends in Biochemical Sciences (1990, pp. 139-142, vol. 15).
Tokichi Miyakawa et al., Role of Metabolism of the Mating Pheromone in Sexual Differentiation of the Heterobasidiomycete Rhodosporidium, Journal of Bacteriology, (1982, pp. 1184-1194, vol. 151, No. 3).
Alterserkrankungen “Alzheimer” und “Parkinson”, PdN-Bio (1999, pp. 26-31, vol. 6, No. 48).
Ehrlich Klaus
Kurz Michael
Segeth Marian Paul
Toti Luigi
Vertesy Laszlo
Aventis Pharma Deutschland GmbH.
Newman Irving
Tucker Zachary C.
LandOfFree
Coniosulfides and their derivatives, processes for preparing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coniosulfides and their derivatives, processes for preparing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coniosulfides and their derivatives, processes for preparing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501984